FeesSafety
Pluang+

Valneva reports positive Phase 2 results for its tetravalent Shigella vaccine candidate showing safety and efficacy.

Company Fundamentals
09 Nov 2026, 08:00 WIB
GlobeNewsWire
View Source
Bullish
Valneva reports positive Phase 2 results for its tetravalent Shigella vaccine candidate showing safety and efficacy.

Valneva announced positive Phase 2 trial results for its tetravalent Shigella vaccine candidate S4V2, showing a favorable safety profile and encouraging immune responses in infants and adults. The infant trial in Kenya demonstrated significant antibody increases and good tolerability, while the controlled human infection model (CHIM) trial in the U.S. showed a statistically significant reduction in shigellosis cases. These results support further clinical development of the vaccine, which targets a major cause of fatal diarrheal disease worldwide with no current licensed vaccine. Valneva plans to analyze full data sets to optimize dosing and schedule for next trial phases.

Valneva's vaccine candidate S4V2 results provide context for health sector interest. For readers following health stocks, here is Pluang's market snapshot as of Nov 09, 2026 13:11 WIB: out of 150 priced US health-sector stocks, 61 rose and 85 fell. Notable movers include ACHC at USD 37.44 (+16.09%), CLPT at USD 8.59 (-15.45%), and FLNA at USD 0.50 (-14.75%).

More News

Dapirolizumab pegol shows higher response rates and sustained remission in SLE patients versus placebo in Phase 3 trial.

Dapirolizumab pegol shows higher response rates and sustained remission in SLE patients versus placebo in Phase 3 trial.

Dapirolizumab pegol (DZP), an investigational biologic for systemic lupus erythematosus (SLE), demonstrated greater treatment response rates compared to placebo when combined with standard care in the Phase 3 PHOENYCS GO trial. Using a novel Treatmen...

Market News
Bullish
5 hours ago
argenx to acquire Unnatural Products for up to $1.15B to boost drug discovery with macrocyclic peptides

argenx to acquire Unnatural Products for up to $1.15B to boost drug discovery with macrocyclic peptides

argenx will acquire Unnatural Products (UNP) for $550 million upfront plus up to $600 million in milestones, totaling about $1.15 billion. UNP specializes in orally-delivered macrocyclic peptides targeting previously undruggable diseases, enhancing a...

Company Fundamentals
Bullish
5 hours ago
argenx to acquire Unnatural Products for up to $1.15B, expanding peptide drug discovery in immunology

argenx to acquire Unnatural Products for up to $1.15B, expanding peptide drug discovery in immunology

argenx announced it will acquire Unnatural Products, Inc. (UNP) for up to $1.15 billion, including upfront and milestone payments. This acquisition adds UNP's macrocyclic peptide discovery platform to argenx's antibody engineering capabilities, broad...

Company Fundamentals
Bullish
5 hours ago
ClearPoint Neuro posts strong Q3 with rising drug delivery revenue and promising future trials.

ClearPoint Neuro posts strong Q3 with rising drug delivery revenue and promising future trials.

ClearPoint Neuro reported solid third-quarter results, driven by increased revenue from its drug delivery services and steady sales in neurosurgery navigation equipment. The company sees encouraging signs for future growth in disposables linked to ca...

Company Fundamentals
Bullish
5 hours ago
Three Bitcoin transfers worth $386.3M occurred in 3 hours, including a $106.9M withdrawal from OKX.

Three Bitcoin transfers worth $386.3M occurred in 3 hours, including a $106.9M withdrawal from OKX.

Within a three-hour period ending Nov. 7, three large Bitcoin transfers totaling $386.3 million were recorded. The biggest transaction moved 1,985 BTC ($150.8M) between unknown wallets, followed by another wallet-to-wallet transfer of 1,694 BTC ($128...

Market News
Neutral
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App